Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Hoffmann-La Roche Clear all
Completed Phase 4 Interventional Results available

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

NCT00412737
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

NCT03371017
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Atezolizumab, Placebo, Gemcitabine, Capecitabine, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT07081958
View directory record Official record
Conditions
Obesity or Overweight
Interventions
RO7795081, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
36
States / cities
Anniston, Alabama • Lake Forest, California • Rancho Cucamonga, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

NCT03038880
View directory record Official record
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

NCT03434379
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Atezolizumab, Bevacizumab, Sorafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05219513
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
RO7443904, Glofitamab, Obinutuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

NCT01235520
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, RO4917838
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Little Rock, Arkansas • Buena Park, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Study of Enfuvirtide in HIV-Positive Subjects

NCT00086710
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Fuzeon
Drug
Lead sponsor
Trimeris
Industry
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

NCT00000688
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

NCT02760797
View directory record Official record
Conditions
Neoplasms
Interventions
Emactuzumab, RO7009789
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

NCT02220842
View directory record Official record
Conditions
Lymphoma
Interventions
Atezolizumab, Obinutuzumab, Tazemetostat
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Duarte, California • Fort Wayne, Indiana • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

NCT05364424
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Glofitamab, Obinutuzumab, Tocilizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Orange, California • Pembroke Pines, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)

NCT01793441
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Placebo, RG7314
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Jul 23, 2026, 2:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

NCT01119859
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Adalimumab, Placebo to tocilizumab, Placebo to adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 23, 2026, 2:22 PM EDT
Enrolling by invitation Phase 3 Interventional

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

NCT05967351
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 4 Interventional

Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

NCT01046955
View directory record Official record
Conditions
End-Stage Renal Disease, Living Donors
Interventions
Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
14 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

NCT04552899
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151 (Zinpentraxin Alfa), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

NCT05164133
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Mount Pleasant, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

A Single Ascending Dose Study of R1671 in Patients With Mild Intermittent Asymptomatic Asthma.

NCT00517816
View directory record Official record
Conditions
Asthma
Interventions
RG1671
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • North Hollywood, California • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional

Radiation Therapy With Capecitabine in Rectal Cancer

NCT00176787
View directory record Official record
Conditions
Rectal Cancer
Interventions
Capecitabine, Radiation, Surgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

NCT05642312
View directory record Official record
Conditions
Uveitic Macular Edema
Interventions
Vamikibart, Sham
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Los Angeles, California • Lakewood, Colorado • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 23, 2026, 2:22 PM EDT